Saptalis Pharmaceuticals’ Likmez (ATI-1501) Receives the US FDA’s Approval for Antimicrobial Infections
Shots:
- The US FDA has approved liquid oral reformulation of the antibiotic metronidazole, ATI-1501 for the treatment of antimicrobial infections in patients with difficulty swallowing pills or who are unable to get injections. The product is expected to be available to patients shortly & the company bring additional products to market for infectious diseases
- The company expects to receive milestones and royalties from Saptalis in upcoming quarters based on the US FDA approval and Saptalis’ commercialization plans.
- Likmez oral suspension is supplied in a 200mL bottle containing 500mg/5mL of metronidazole in a strawberry peppermint flavor. Patent coverage provides drug market exclusivity through at least 2039
Ref: Businesswire | Image: Saptalis Pharmaceuticals
Related News:- Roche Launches Cobas MTB-RIF/INH Test for the Detection of Antimicrobial Resistance in Tuberculosis
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
